ArticleJAMA2021
Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017.
Article in JAMA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 291 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Intervention Mapping Approach to Closing the Gap in Maternal OUD and Infant NAS Care
Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine
Who cites it
291 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Prenatal opioid exposure, and health, social and educational outcomes for school-aged children: A systematic review.Addiction (Abingdon, England) · 2026Pooled it
- Neurodevelopmental outcomes of prenatal opioid exposure and neonatal opioid withdrawal syndrome: A systematic review from birth to early adulthood.Journal of perinatology : official journal of the California Perinatal Association · 2026Pooled it
- Evidence-based framework for identifying opioid use disorder in administrative data: A systematic review and methodological development study.Pain medicine (Malden, Mass.) · 2026Pooled it
- Interventions for opioid use disorder during pregnancy: a scoping review.Frontiers in psychiatry · 2026Pooled it
- Prenatal incidence of cleft lip/palate and cocaine abuse in parents: a systematic review and meta-analysis.BMC oral health · 2024Pooled it
- Maternal Area of Residence and Outcomes for Mother-Infant Dyads with Perinatal Opioid Exposure.American journal of perinatology · 2026Trial
- Efficacy of stochastic vibro-tactile stimulation for newborns at risk of neonatal opioid withdrawal syndrome.Pediatric research · 2026Trial
- Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome.Clinical and translational science · 2025Trial
- Patient navigation for pregnant individuals with opioid use disorder: Results of a randomized multi-site pilot trial.Addiction (Abingdon, England) · 2024Trial
- Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal.The New England journal of medicine · 2023Trial
- Duration of Medication Use for Opioid Use Disorder and Risk of Postpartum Overdose and Death.JAMA network open · 2026Article
- Neonatal Outcomes Associated with Maternal-Factor-Related Diagnoses: Real-World Evidence from a National Inpatient Database (2010-2025).Medical sciences (Basel, Switzerland) · 2026Article
- Extended-release injection vs sublingual buprenorphine for illicit opioid use in pregnant patients with depression and/or anxiety.Drug and alcohol dependence · 2026Article
- Psychostimulant Continuation and Postpartum Mental Health in Pregnant People With Attention-Deficit/Hyperactivity Disorder.Obstetrics and gynecology · 2026Article
- The Gut-Brain Axis in Fetal Alcohol Spectrum Disorder (FASD): Why the Gut Shapes Behavior, Depression, and Self-Injurious Behavior in Children with Prenatal Alcohol Exposure-A Narrative Review with a Proposal for Staged Nutritional and Microbiological Intervention.Journal of clinical medicine · 2026Review
- Trends and Characteristics of Opioid Use During Pregnancy Between 2010 and 2023: A French Nationwide Drug Utilization Study.European journal of pain (London, England) · 2026Article
- A comparison of dual vs. single diagnostic code approaches for neonatal opioid withdrawal syndrome surveillance in neonates ≥ 35 weeks gestational age.BMC pediatrics · 2026Observational
- Implementation and evaluation of a secret shopper methodology to examine access to prenatal care for patients with opioid use disorder.BMC pregnancy and childbirth · 2026Article
- Adolescent prefrontal and amygdala molecular signatures of perinatal morphine versus buprenorphine exposure in mice.Neurotoxicology · 2026Article
- Nursing Students' Knowledge, Attitudes, and Skills Related to Perinatal Substance Use.Substance use & addiction journal · 2026Article
231 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Substantial increases in both neonatal abstinence syndrome (NAS) and maternal opioid use disorder have been observed through 2014. Objective: To examine national and state variation in NAS and maternal opioid-related diagnoses (MOD) rates in 2017 and to describe national and state changes since 2010 in the US, which included expanded MOD codes (opioid use disorder plus long-term and unspecified use) implemented in International Classification of Disease, 10th Revision, Clinical Modification. Design, Setting, and Participants: Repeated cross-sectional analysis of the 2010 to 2017 Healthcare Cost and Utilization Project's National Inpatient Sample and State Inpatient Databases, an all-payer compendium of hospital discharge records from community nonrehabilitation hospitals in 47 states and the District of Columbia. Exposures: State and year. Main Outcomes and Measures: NAS rate per 1000 birth hospitalizations and MOD rate per 1000 delivery hospitalizations. Results: In 2017, there were 751 037 birth hospitalizations and 748 239 delivery hospitalizations in the national sample; 5375 newborns had NAS and 6065 women had MOD documented in the discharge record. Mean gestational age was 38.4 weeks and mean maternal age was 28.8 years. From 2010 to 2017, the estimated NAS rate significantly increased by 3.3 per 1000 birth hospitalizations (95% CI, 2.5-4.1), from 4.0 (95% CI, 3.3-4.7) to 7.3 (95% CI, 6.8-7.7). The estimated MOD rate significantly increased by 4.6 per 1000 delivery hospitalizations (95% CI, 3.9-5.4), from 3.5 (95% CI, 3.0-4.1) to 8.2 (95% CI, 7.7-8.7). Larger increases for MOD vs NAS rates occurred with new International Classification of Disease, 10th Revision, Clinical Modification codes in 2016. From a census of 47 state databases in 2017, NAS rates ranged from 1.3 per 1000 birth hospitalizations in Nebraska to 53.5 per 1000 birth hospitalizations in West Virginia, with Maine (31.4), Vermont (29.4), Delaware (24.2), and Kentucky (23.9) also exceeding 20 per 1000 birth hospitalizations, while MOD rates ranged from 1.7 per 1000 delivery hospitalizations in Nebraska to 47.3 per 1000 delivery hospitalizations in Vermont, with West Virginia (40.1), Maine (37.8), Delaware (24.3), and Kentucky (23.4) also exceeding 20 per 1000 delivery hospitalizations. From 2010 to 2017, NAS and MOD rates increased significantly for all states except Nebraska and Vermont, which only had MOD increases. Conclusions and Relevance: In the US from 2010 to 2017, estimated rates of NAS and MOD significantly increased nationally and for the majority of states, with notable state-level variation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.